ELCA CORONARY LASER ATHERECTOMY CATHETER
Report
- Report Number
- 3007284006-2026-00195
- Event Type
- Death
- Date Received
- May 6, 2026
- Date of Event
- May 13, 2024
- Report Date
- October 1, 2025
- Manufacturer
- SPECTRANETICS CORPORATION
- Product Code
- LPC
- PMA / PMN Number
- P910001
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- CH
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
A2) PATIENT AGE - MEAN AGE 64.5 ± 10.6. A3A) PATIENT SEX - 47 MALES, 8 FEMALES. A4) PATIENT WEIGHT - 25.6 (BMI). A3B/A5/A6) SPECIFIC PATIENT/CASE DETAIL WAS NOT PROVIDED. B4) DATE LISTED IS THE DATE THE MANUFACTURER BECAME AWARE. B6) PATIENT INFORMATION REGARDING RELEVANT TESTS/LABORATORY - SPECIFIC PATIENT/CASE DETAIL WAS NOT PROVIDED. D4/H4) THE LOT NUMBER WAS NOT PROVIDED, THUS THE FOLLOWING INFORMATION IS UNKNOWN: MODEL/CATALOG NUMBER, DEVICE SERIAL NUMBER, UNIQUE ID, EXPIRATION DATE, AND MANUFACTURE DATE. E) ALTHOUGH THE JOURNAL ARTICLE ORIGINATED FROM CHINA, PHYSICIAN AND FACILITY INFORMATION ARE UNKNOWN; THEREFORE, THE INFORMATION LISTED IS THE CORRESPONDING AUTHOR OF THE JOURNAL ARTICLE. G3) THIS REPORT IS BEING SUBMITTED AS PART OF A RETROSPECTIVE REVIEW FOR LITERATURE MDR PER CAPA 207. H3) THE DEVICE WAS DISCARDED, THUS NO PRODUCT INVESTIGATION WAS PERFORMED. H6) PER IFU, DEATH IS LISTED AS A POTENTIAL ADVERSE EVENT WITH USE OF THE ELCA DEVICES. SUBMISSION OF THIS REPORT DOES NOT, IN ITSELF, REPRESENT A CONCLUSION BY THE MANUFACTURER AND/OR AUTHORIZED REPRESENTATIVE OR THE NATIONAL COMPETENT AUTHORITY THAT THE CONTENT OF THIS REPORT IS COMPLETE OR ACCURATE, THAT THE MEDICAL DEVICE(S) LISTED FAILED IN ANY MANNER AND/OR THAT THE MEDICAL DEVICE(S) CAUSED OR CONTRIBUTED TO AN ALLEGED DEATH OR DETERIORATION IN THE STATE OF THE HEALTH OF ANY PERSON.
A PHILIPS EMPLOYEE BECAME AWARE OF A JOURNAL ARTICLE (PUBLISHED ONLINE 13MAY2024) ¿DEBULKING WITH EXCIMER LASER CORONARY ANGIOPLASTY VERSUS BALLOON ANGIOPLASTY IN PATIENTS WITH IN STENT RESTENOSIS (ELDISR STUDY): A RANDOMIZED CONTROLLED TRIAL¿. THE STUDY RETROSPECTIVELY AIMED TO EVALUATE THE EFFECT OF ELCA-BASED LESION PREPARATION ON THE CLINICAL OUTCOMES OF IN-STENT RESTENOSIS (ISR) PATIENTS TREATED WITH STANDARD DRUG-COATED BALLOON (DCB) ANGIOPLASTY. A TOTAL OF 110 PATIENTS WITH ISR WERE ENROLLED IN THE STUDY BETWEEN OCTOBER 2021 AND JUNE2023. ALL LESIONS WERE SEQUENTIALLY TREATED WITH SPECTRANETICS ELCA LASER ATHERECTOMY CATHETERS. PROCEDURAL COMPLICATIONS INCLUDED 1 TYPE C OR ABOVE DISSECTION AND 4 NO-REFLOW. DURING THE 1-YEAR FOLLOW-UP, 2 PATIENTS EXPERIENCED MYOCARDIAL INFARCTION AND 5 REQUIRED REPEAT TARGET LESION REVASCULARIZATION (MDR # 3007284006-2026-00194). ADDITIONALLY, 2 PATIENTS EXPERIENCED CARDIAC DEATH (MDR # 3007284006-2026-00195). ALTHOUGH GENERALIZED PATIENT INFORMATION/MEDICAL HISTORY WAS LISTED WITHIN THE JOURNAL ARTICLE, SPECIFIC PATIENT/CASE DETAIL WAS NOT PROVIDED FOR THE ADVERSE EVENTS INVOLVING THE SPECTRANETICS DEVICES. ADDITIONALLY, THE DATE OF PROCEDURE WAS NOT LISTED FOR THESE EVENTS; THEREFORE, 13MAY2024 HAS BEEN USED, THE DATE OF PUBLICATION. HE, P ET AL_2024_DEBULKING WITH EXCIMER LASER CORONARY ANGIOPLASTY VERSUS BALLOON ANGIOPLASTY IN PATIENTS WITH IN STENT RESTENOSIS (ELDISR STUDY): A RANDOMIZED CONTROLLED TRIAL. LASERS IN SURGERY AND MEDICINE, 2025; 57:329¿338. HTTPS://DOI.ORG/10.1002/LSM.70013. THIS REPORT CAPTURES THE DEATHS THAT OCCURRED AFTER USE OF THE ELCA DEVICE. THERE WAS NO ALLEGED MALFUNCTION OF ANY SPECTRANETICS DEVICES IN USE DURING THE PROCEDURE.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 463738 | ELCA CORONARY LASER ATHERECTOMY CATHETER | DEVICE, ANGIOPLASTY, LASER, CORONARY | LPC | SPECTRANETICS CORPORATION |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | NA | Unknown | CUTTING BALLON.| DCB (SEQUENTPLEASE, B. BRAUN SURGICAL).| NONCOMPLIANT BALLON.| OPTICAL COHERENCE TOMOGRAPHY.| SPECTRANETICS CVX-300 EXCIMER LASER SYSTEM. |